TRAM-34
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 522416

CAS#: 289905-88-0

Description: TRAM-34 is a highly selective blocker of intermediate conductance Ca2+-activated K+ channels (KCa3.1) that has been shown to suppress the reactivation of lymphocytes by mitogenic stimuli without blocking cytochrome P450.


Chemical Structure

img
TRAM-34
CAS# 289905-88-0

Theoretical Analysis

MedKoo Cat#: 522416
Name: TRAM-34
CAS#: 289905-88-0
Chemical Formula: C22H17ClN2
Exact Mass: 344.10803
Molecular Weight: 344.84
Elemental Analysis: C, 76.63; H, 4.97; Cl, 10.28; N, 8.12

Price and Availability

Size Price Availability Quantity
10.0mg USD 230.0 2 Weeks
25.0mg USD 385.0 2 Weeks
50.0mg USD 630.0 2 Weeks
Bulk inquiry

Synonym: TRAM-34; TRAM34; TRAM 34

IUPAC/Chemical Name: 1-[(2-Chlorophenyl)diphenylmethyl]-1H-pyrazole

InChi Key: KBFUQFVFYYBHBT-UHFFFAOYSA-N

InChi Code: InChI=1S/C22H17ClN2/c23-21-15-8-7-14-20(21)22(25-17-9-16-24-25,18-10-3-1-4-11-18)19-12-5-2-6-13-19/h1-17H

SMILES Code: C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CC=N4

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 344.84 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Ye JH, Pao LH. Using Visualized Matrix Effects to Develop and Improve LC-MS/MS Bioanalytical Methods, Taking TRAM-34 as an Example. PLoS One. 2015 Apr 24;10(4):e0118818. doi: 10.1371/journal.pone.0118818. eCollection 2015. PubMed PMID: 25909956; PubMed Central PMCID: PMC4409340.

2: Lin H, Zheng C, Li J, Yang C, Hu L. Ca2+ -activated K+ channel-3.1 blocker TRAM-34 alleviates murine allergic rhinitis. Int Immunopharmacol. 2014 Dec;23(2):642-8. PubMed PMID: 25466273.

3: Ongerth T, Russmann V, Fischborn S, Boes K, Siegl C, Potschka H. Targeting of microglial KCa3.1 channels by TRAM-34 exacerbates hippocampal neurodegeneration and does not affect ictogenesis and epileptogenesis in chronic temporal lobe epilepsy models. Eur J Pharmacol. 2014 Oct 5;740:72-80. doi: 10.1016/j.ejphar.2014.06.061. Epub 2014 Jul 10. PubMed PMID: 25016931.

4: Freise C, Querfeld U. Inhibition of vascular calcification by block of intermediate conductance calcium-activated potassium channels with TRAM-34. Pharmacol Res. 2014 Jul;85:6-14. doi: 10.1016/j.phrs.2014.04.013. Epub 2014 May 6. PubMed PMID: 24813858.

5: Agarwal JJ, Zhu Y, Zhang QY, Mongin AA, Hough LB. TRAM-34, a putatively selective blocker of intermediate-conductance, calcium-activated potassium channels, inhibits cytochrome P450 activity. PLoS One. 2013 May 7;8(5):e63028. doi: 10.1371/journal.pone.0063028. Print 2013. PubMed PMID: 23667566; PubMed Central PMCID: PMC3646888.

6: Girodet PO, Ozier A, Carvalho G, Ilina O, Ousova O, Gadeau AP, Begueret H, Wulff H, Marthan R, Bradding P, Berger P. Ca(2+)-activated K(+) channel-3.1 blocker TRAM-34 attenuates airway remodeling and eosinophilia in a murine asthma model. Am J Respir Cell Mol Biol. 2013 Feb;48(2):212-9. doi: 10.1165/rcmb.2012-0103OC. Epub 2012 Nov 29. PubMed PMID: 23204391; PubMed Central PMCID: PMC4035224.

7: Freise C, Ruehl M, Seehofer D, Hoyer J, Somasundaram R. The inhibitor of Ca(2+)-dependent K+ channels TRAM-34 blocks growth of hepatocellular carcinoma cells via downregulation of estrogen receptor alpha mRNA and nuclear factor-kappaB. Invest New Drugs. 2013 Apr;31(2):452-7. doi: 10.1007/s10637-012-9879-6. Epub 2012 Oct 2. PubMed PMID: 23054207.

8: Quast SA, Berger A, Buttstädt N, Friebel K, Schönherr R, Eberle J. General Sensitization of melanoma cells for TRAIL-induced apoptosis by the potassium channel inhibitor TRAM-34 depends on release of SMAC. PLoS One. 2012;7(6):e39290. doi: 10.1371/journal.pone.0039290. Epub 2012 Jun 18. PubMed PMID: 22723988; PubMed Central PMCID: PMC3377761.

9: Chen YJ, Raman G, Bodendiek S, O'Donnell ME, Wulff H. The KCa3.1 blocker TRAM-34 reduces infarction and neurological deficit in a rat model of ischemia/reperfusion stroke. J Cereb Blood Flow Metab. 2011 Dec;31(12):2363-74. doi: 10.1038/jcbfm.2011.101. Epub 2011 Jul 13. PubMed PMID: 21750563; PubMed Central PMCID: PMC3323185.

10: Roy JW, Cowley EA, Blay J, Linsdell P. The intermediate conductance Ca2+-activated K+ channel inhibitor TRAM-34 stimulates proliferation of breast cancer cells via activation of oestrogen receptors. Br J Pharmacol. 2010 Feb 1;159(3):650-8. doi: 10.1111/j.1476-5381.2009.00557.x. Epub 2009 Dec 24. PubMed PMID: 20050851; PubMed Central PMCID: PMC2828028.

TRAM-34

10.0mg / USD 230.0